Adia Nutrition

What Adia Nutrition does

Adia Nutrition, Inc. (OTCQB: ADIA, rebranding to Adia Med, Inc.) is a publicly traded regenerative medicine company headquartered in Winter Park, Florida, that transitioned from shell-company status into operating regenerative medicine and biologics in 2025. The company operates through two wholly-owned subsidiaries — Adia Med of Winter Park, LLC, which runs the clinical practice, and Adia Labs, LLC, which manufactures and distributes biologics — and holds an 18% minority equity stake in Cement Factory, LLC. Its core product, AdiaVita, is a proprietary umbilical cord blood-derived stem cell and exosome biologic protected by a filed USPTO provisional patent and trademark, administered at its own clinic and supplied to partner clinics under IRB-approved clinical study protocols targeting autism spectrum disorder, chronic kidney disease, and lower back pain.

The business runs on a patient-pay model in which individuals fund treatments and clinical trial participation out of pocket (clinical study fees range from $5,000 to $15,000 per participant). The company is generating clinical evidence to support future coverage by private and government insurers, and has partnered with an independent health care sharing ministry serving 250,000+ members that now accepts up to three stem cell treatments per client. Additional revenue streams include biologic product sales to partner clinics and a newly launched Regenerative Aesthetics division offering facial rejuvenation, hair restoration, and microneedling. Go-to-market combines direct-to-consumer clinic visits, B2B inside sales (CRO Dawn Bell targeting physician/clinic partners), and community-led growth via academic collaborations (e.g., UCF CARD) and media partnerships (e.g., Dr. Asa Andrew).

FY2025 revenue reached $700,508 (up from $6,380 in FY2024), but the company reported an operating loss of $366,492, a net loss of $395,464, and an accumulated deficit of $15.9M, with auditors raising substantial doubt about going-concern status. The company achieved full SEC reporting status via its Form 10 effective February 3, 2026, and is exploring a potential NASDAQ uplisting while expanding its Winter Park facility and adding clinical pipeline capacity.

Name

Adia Nutrition

Legal name

ADIA Nutrition, Inc.

Website

https://adianutrition.com

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Adia Nutrition (rebranding to Adia Med) is a publicly traded regenerative medicine company that operates a Winter Park, Florida clinic and a biologics manufacturing subsidiary, selling its proprietary AdiaVita stem cell and exosome product directly to patients and clinical trial participants.

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Diet and Weight Reducing Centers (812191)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Regenerative medicine
• Stem cell therapy
• Biologic products
• Clinical research
• Regenerative aesthetics

Headquarters

HQ city

Kurtistown

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Biologic Product Sales: Sales of proprietary AdiaVita stem cell and exosome products used in treatments and clinical studies. Revenue derived from supplying regenerative products to the company's own clinic and partner clinics.
2. Medical Procedures: Patient-paid fees for clinical treatments and procedures at Adia Med clinic. Clinical studies charge participation fees ($5,000-$15,000 per participant) in a patient-pay model.
3. Healthcare Sharing Ministry Partnerships: Revenue from health care sharing ministries that accept stem cell treatments, removing insurance barriers and enabling families to pursue regenerative care with partial coverage.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Adia Nutrition (rebranding to Adia Med) operates a vertically integrated regenerative medicine business that manufactures and distributes the proprietary AdiaVita umbilical cord blood-derived stem cell and exosome biologic product through its Adia Labs subsidiary, and delivers patient-facing stem cell therapies, regenerative aesthetics, and IRB-approved clinical research studies through its Adia Med clinic in Winter Park, Florida. The company addresses chronic conditions including autism spectrum disorder, chronic kidney disease, and lower back pain using a patient-pay model.

Product overview

Adia Nutrition (now rebranding as Adia Med) operates a dual-division model comprising Adia Med clinic and Adia Labs biologics division. The core product is AdiaVita, a proprietary umbilical cord blood-derived stem cell and exosome product used across multiple clinical programs. Adia Med provides patient-facing regenerative medicine services including stem cell therapies, while Adia Labs manufactures and distributes regenerative products. The company also offers Regenerative Aesthetics services and operates multiple IRB-approved clinical studies for autism, kidney disease, and lower back pain.

Differentiator

Problem solved

Functional benefit

Products and services

• AdiaVita Stem Cell Product Proprietary umbilical cord blood-derived stem cell and exosome biologic product manufactured by Adia Labs and used as the core therapeutic input across the company's clinical services, clinical studies, and partner clinics.
• Adia Med Clinic Services

Quantifiable outcome

• Revenue growth from $6,380 (2024) to $700,508 (2025) - over 100x increase
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Independent Health Care Sharing MinistrycoreChannel Partner/ Reseller/ Distributor · 26 May 2026Health care sharing ministry serving more than 250,000 members nationwide now accepts up to three stem cell treatments per client. A family of three is currently undergoing AdiaVita treatment at one of the company's affiliate clinics. The company continues reaching out to other health care sharing programs.
• Atlanta CliniccoreStrategic or Co-development Partner · 8 April 2026Strategic partnership with a prominent Atlanta clinic to conduct an Autism Spectrum Disorder clinical study. Adia Labs serves as the exclusive supplier of AdiaVita for the study enrolling 100 participants each receiving 3 infusions. The goal is to generate clinical evidence for insurance coverage from both private and government insurers.
• UCF CARD (Center for Autism and Related Disabilities)minorGTM or Marketing Partner · 24 March 2026Collaboration with UCF CARD for a live Zoom presentation to discuss the ongoing clinical study evaluating AdiaVita for children with Autism Spectrum Disorder. UCF CARD is allowing Adia Nutrition to present information about its research to families considering enrollment.
• Amy Dalrymple, APRNcoreOthers · 17 March 2026Appointment of Amy Dalrymple, former Mrs. Florida United States and board-certified nurse practitioner, as head of Regenerative Aesthetics Division. She brings over a decade of specialized experience in aesthetic medicine and will oversee advanced facial rejuvenation, hair restoration, and other regenerative treatments.
• Dr. Asa AndrewcoreGTM or Marketing Partner · 1 December 2025Partnership with Dr. Asa Andrew, America's #1 Health Talk Show Host and physician, to promote stem cell therapies through content creation and media outreach. The collaboration aims to educate the public on regenerative medicine and expand access to stem cell treatments.

Scale indicators9 records

Recent moves11 records

Expansion highlights6 records

Market position

Competitive moat4 records

Key highlights6 records

Customer concentration

• Xx.com/adia_nutrition

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adia Nutrition